Suzie Lyn Sheehy

Country flagUnited Kingdom

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Background and purpose The lack of equitable access to radiotherapy (RA) linear accelerators (LINACs) is a substantial barrier to cancer care in low‐ and middle‐income countries (LMICs). These nations are expected to bear up to 75% of cancer‐related deaths globally by 2030. State‐of‐the‐art LINACs in LMICs experience major issues in terms of robustness, with mechanical and electrical breakdowns resulting in downtimes ranging from days to months. While existing research has identified the higher failure frequency and downtimes between LMICs (Nigeria, Botswana) compared to high‐income countries (HICs, the UK), there has been a need for additional data and study particularly relating to multileaf collimators (MLCs). Materials and methods This study presents for the first time the analysis of data gathered through a dedicated survey and workshop including participants from 14 Indonesian hospitals, representing a total of 19 LINACs. We show the pathways to failure of radiotherapy LINACs and frequency of breakdowns with a focus on the MLC subsystem. Results This dataset shows that LINACs throughout Indonesia are out of operation for seven times longer than HICs, and the mean time between failures of a LINAC in Indonesia is 341.58 h or about 14 days. Furthermore, of the LINACs with an MLC fitted, % of all mechanical faults are due to the MLC, and % of cases requiring a replacement component are related to the MLC. Conclusion These results highlight the pressing need to improve robustness of RT technology for use in LMICs, highlighting the MLC as a particularly problematic component. This work motivates a reassessment of the current generation of RT LINACs and demonstrates the need for dedicated efforts toward a future where cancer treatment technology is robust for use in all environments where it is needed.

Year:

2022

Year:

2022

Collaborators (5)

Matteo Volpi

University of Melbourne

AUSTRALIA
View details

Frank Van den Heuvel

University of Oxford

UNITED KINGDOM
View details

Duncan Butler

Australian Nuclear Science and Technology Organisation

AUSTRALIA
View details

Roger Rassool

University of Melbourne

AUSTRALIA
View details

Manjit Dosanjh

Professor, Senior Advisor for Medical Applications

CERN

SWITZERLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.